Search Results
Aug 19, 2026, 09:30 ET Monteris Medical Announces Publication of Landmark Study on 787 Brain Tumor Patients Treated with NeuroBlate® Laser Interstitial Thermal Therapy (LITT)
Journal of Clinical Oncology (JCO), this ninth manuscript from LAANTERN analyzes outcomes from 787 tumor patients treated exclusively with NeuroBlate across 25 U.S. centers, establishing
More news about: Monteris Medical
Aug 12, 2026, 09:00 ET Jiro Personalizes ASCO Journals and Guideline Content for Every Oncologist
Health today announced a multi-year content agreement with Wolters Kluwer Health, publisher of the American Society of Clinical Oncology's (ASCO®) JCO family of journals. Clinical evidence from ASCO's journals, including guideline articles, will now be integrated into Jiro's Practice Intelligence platform
More news about: Jiro Health
Jul 30, 2026, 08:30 ET Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
carcinoma after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study. J Clin Onc. May 31, 2026. doi:10.1200/JCO-26-01042.6 ClinicalTrials.gov. A study of amivantamab alone or in addition to other treatment agents in participants with recurrent/metastatic
More news about: Johnson & Johnson
Jul 29, 2026, 10:20 ET Florida Cancer Specialists & Research Institute Physician Executive Examines Leadership Strategies Shaping the Future of Cancer Care in Published Article
The article, coauthored with Texas Oncology medical oncologist and hematologist Debra Patt, MD, PhD, MBA and published in JCO® Oncology Practice, examines how scientific breakthroughs, precision medicine and digital innovation are reshaping cancer care while creating new
More news about: Florida Cancer Specialists & Research Institute
Jul 14, 2026, 09:02 ET ISPE Names Jose Caraballo-Oramas as Executive Chair and Connie Langer as Conference Chair for the 2026 ISPE Annual Meeting & Expo
ISPE) has announced Jose Caraballo-Oramas, Executive Chair, Founder, and Principal, JCO Global Advisory LLC, as the Executive Chair of the
More news about: ISPE
Jul 02, 2026, 06:30 ET Partner Therapeutics Announces Publication of Results From the eNRGy Trial of Zenocutuzumab in Patients with NRG1+ Cholangiocarcinoma in Journal of Clinical Oncology (JCO)
commitment to advancing therapies for patients with unmet medical needs, including those with NRG1 fusion-positive cholangiocarcinoma. The JCO publication further supports the therapeutic potential of zenocutuzumab in this rare population, which has historically experienced limited treatment
More news about: Partner Therapeutics, Inc.
Jun 30, 2026, 09:00 ET AccessHope Launches CME Program and Clinical Advisory Board to Make Evidence-Based Cancer Care the Standard in Every Community
study published in JCO Oncology Practice. The analysis of 5,137 cases across 50 states found expert subspecialist review resulted in treatment‑change recommendations in
More news about: AccessHope
Jun 02, 2026, 08:59 ET Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
Journal of Clinical Oncology (JCO). "The Phase 3 SENTRY results represent a meaningful advance for patients with myelofibrosis and underscore the promise of combining selinexor
More news about: Karyopharm Therapeutics Inc.
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study. Epub May 31, 2026. doi:10.1200/JCO-26-01042.3 Zebralla V, Wichmann G, Pirlich M, et al. Dysphagia, voice problems, and pain in head and neck cancer patients. Eur
More news about: Johnson & Johnson
May 29, 2026, 14:00 ET RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2. J Clin Oncol. 2026;44(1):54-65. doi:10.1200/JCO-24-02835 3 Kim EY, Cho EN, Park HS, et al. Compound EGFR mutation is frequently detected with co-mutations of actionable genes
More news about: Johnson & Johnson
May 27, 2026, 18:18 ET U.S. FDA Approves DECNUPAZ™ (pivekimab sunirine-pvzy) for Treatment of Adult Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
https://ascopubs.org/doi/10.1200/JCO-25-02083. Accessed April 15, 2026.Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN. Available
More news about: AbbVie
May 21, 2026, 17:30 ET Canopy Studies Selected for Oral and Poster Presentations at 2026 ASCO Annual Meeting
Large-Scale Implementation of an Electronic Patient- Reported Outcome Remote Monitoring System for Patients on Active Treatment at a Community Cancer Center. JCO Oncology Practice, 18(12), e1918-e1926. DOI: 10.1200/OP.22.001805 Derman, B. A., Essell, J. H., Kolodziej, M. A., Kwiatkowsky, L.,
More news about: Canopy
May 14, 2026, 08:00 ET Illinois CancerCare, P.C. Partners with Canopy to Expand Patient Access and Care Between Visits
Large-Scale Implementation of an Electronic Patient- Reported Outcome Remote Monitoring System for Patients on Active Treatment at a Community Cancer Center. JCO Oncology Practice, 18(12), e1918-e1926. DOI: 10.1200/OP.22.001805 Derman, B. A., Essell, J. H., Kolodziej, M. A., Kwiatkowsky, L.,
More news about: Canopy
Apr 20, 2026, 08:00 ET Sapience Therapeutics Presents First Clinical Results from Phase 2 Study of ST316, First-in-Class β-catenin Antagonist, in Second-Line Colorectal Cancer at the American Association for Cancer Research (AACR) Annual Meeting 2026
Iwamoto et al, Ann Oncol 2015 (EAGLE Study); Van Cutsem et al, JCO 2012 (VELOUR Study); Tabernero et al, Lancet Oncol 2015 (RAISE Study); Bennouna et al, Lancet Oncol 2013 (ML18147 Study); Masi et al, Ann Oncol 2015 (BEBYP Study); Giantonio et al, JCO 2007 (E3200 Study)
More news about: Sapience Therapeutics, Inc.
Apr 16, 2026, 11:03 ET /C O R R E C T I O N -- Boehringer Ingelheim/
2020 Jul;145:195-204.Presley, C. J. et al. Functional Disability Among Older Versus Younger Adults With Advanced Non–Small-Cell Lung Cancer. JCO Oncol Pract. 2021 May 3;17(6):e848–e858.Galogre M, et al. A review of HER2 overexpression and somatic mutations in cancers, Critical Reviews
More news about: Boehringer Ingelheim
Apr 15, 2026, 08:30 ET Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients
Research published in JCO Oncology Practice found that 70% of U.S. counties had no active cancer treatment trials, leaving nearly one in five Americans ages 55 and older without
More news about: Caris Life Sciences
Apr 06, 2026, 09:00 ET Abbott recebe aprovação regulatória no Brasil de serplulimabe, novo medicamento biológico para o tratamento de câncer de pulmão de pequenas células com doença extensa, oferecendo uma nova alternativa para pacientes
for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international phase 3 ASTRUM-005 study. JCO 42, 8100-8100(2024)European Society for Medical Oncology. ESMO-MCBS scorecard 470: Serplulimab. ESMO. Published November 8, 2024. Accessed September
More news about: Abbott
Mar 31, 2026, 05:00 ET Resilience Care Expands to U.S. Market, Adds Veteran Digital Health Leaders to Support Growth with Oncology Providers
Care among healthcare professionals in Europe.[4] Basch, JCO 2016 ; Basch et al, JAMA 2022 ; Mir et al, Nat Med 2022 ; Patt, JCO Clin Informatics 2023.[5] Basch, JCO 2016.Logo:
More news about: Resilience Care
Mar 10, 2026, 09:02 ET Registrational Phase III AMPLIFY trial: Target number of participants achieved
. 64Cu-SAR-bisPSMA (PROPELLER) positron emission tomography (PET) imaging in patients with confirmed prostate cancer. JCO 41, 5039-5039(2023). DOI:10.1200/JCO.2023.41.16_suppl.5039Global
More news about: Clarity Pharmaceuticals
Feb 02, 2026, 09:08 ET International Cancer Organizations Work Together to Meet the Needs of Women with Cancer in Vietnam
NCCN.org for more information.1 Giang Nguyen Huong et al. Thirty-Year Trends (1991-2020) in Breast Cancer Incidence Rates: Hanoi, Vietnam. JCO Glob Oncol 11, e2400570(2025). DOI:10.1200/GO-24-005702 Phuong Dung (Yun) Trieu, Claudia Mello-Thoms, Patrick C. Brennan. Female
More news about: National Comprehensive Cancer Network
Feb 01, 2026, 21:08 ET Organisasi Kanker Internasional Bekerja Sama Untuk Memenuhi Kebutuhan Pasien Kanker Wanita di Vietnam
informasi lebih lanjut.1 Giang Nguyen Huong et al. Thirty-Year Trends (1991-2020) in Breast Cancer Incidence Rates: Hanoi, Vietnam. JCO Glob Oncol 11, e2400570(2025). DOI:10.1200/GO-24-005702 Phuong Dung (Yun) Trieu, Claudia Mello-Thoms, Patrick C. Brennan. Female
More news about: National Comprehensive Cancer Network
Feb 01, 2026, 21:08 ET Các Tổ Chức Ung Thư Quốc Tế Hợp Tác Đáp Ứng Nhu Cầu của Bệnh Nhân Ung Thư Nữ tại Việt Nam
Thirty-Year Trends (1991-2020) in Breast Cancer Incidence Rates: Hanoi, Vietnam (Xu Hướng Tỷ Lệ Mắc Ung Thư Vú trong 30 Năm (1991-2020) tại Hà Nội, Việt Nam). JCO Glob Oncol 11, e2400570(2025). DOI:10.1200/GO-24-005702 Triệu Phương Dung (Yun Trieu), Claudia Mello-Thoms, Patrick C. Brennan. Female
More news about: National Comprehensive Cancer Network
Feb 01, 2026, 20:08 ET 國際癌症組織攜手合作 回應越南女性癌症患者的治療需要
NCCN.org。1 Giang Nguyen Huong et al. Thirty-Year Trends (1991-2020) in Breast Cancer Incidence Rates: Hanoi, Vietnam. JCO Glob Oncol 11, e2400570 (2025). DOI:10.1200/GO-24-005702 Phuong Dung (Yun) Trieu、Claudia Mello-Thoms、Patrick C. Brennan. Female breast
More news about: National Comprehensive Cancer Network
Feb 01, 2026, 19:08 ET ベトナムの女性がん患者のニーズに応えるため、国際的ながん関連組織が協力
NCCN.org をご覧ください。1 Giang Nguyen Huong et al. Thirty-Year Trends (1991-2020) in Breast Cancer Incidence Rates: Hanoi, Vietnam. JCO Glob Oncol 11, e2400570(2025). DOI:10.1200/GO-24-005702 Phuong Dung (Yun) Trieu, Claudia Mello-Thoms, Patrick C. Brennan. Female
More news about: National Comprehensive Cancer Network
Feb 01, 2026, 19:08 ET 국제 암 기관들, 베트남 여성 암 환자의 치료 수요 충족 위해 협력
NCCN.org를 방문하면 더 자세한 내용을 확인할 수 있다.¹ 지앙 응우엔 흐엉(Giang Nguyen Huong) 외, 「베트남 하노이 유방암 발생률의 30년 추이(1991~2020)」, JCO Global Oncology 11, e2400570(2025). DOI:10.1200/GO-24-00570² 푸엉 중(윤) 찌에우(Phuong Dung (Yun) Trieu), 클라우디아 멜로-톰스(Claudia Mello-Thoms), 패트릭 C.
More news about: National Comprehensive Cancer Network